IP Library Granted Patent US 8,765,652
Granted Patent B2
US 8,765,652 · App. 13/531,924 · Granted Jul 1, 2014

Method of making a formulation for deactivating nucleic acids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,765,652
App. No.
13/531,924
Granted
Jul 1, 2014
Kind
B2
Abstract

The present invention relates to reagents for use in deactivating nucleic acids and methods of making and using the same.

Claims (23)

1. A method of making a formulation for deactivating nucleic acids, the method comprising the steps of:

(a) separately dissolving solid forms of a corrosion-inhibiting agent and a wetting agent, the corrosion-inhibiting agent being phosphate, borate or sodium bicarbonate, and the wetting agent being a detergent or a surfactant;

(b) combining together the dissolved forms of the corrosion-inhibiting agent and the wetting agent to form a first mixture;

(c) combining together the first mixture with a solubilizing agent to form a second mixture, the solubilizing agent being an organic solvent or an emulsifying agent; and

(d) combining together the second mixture and a deactivating agent to form the formulation, the deactivating agent being sodium hypochlorite or dichloroisocyanurate,

wherein the corrosion-inhibiting agent is present in the formulation at a concentration of from about 10 mM to about 750 mM;

wherein the wetting agent is present in the formulation at a concentration of from about 0.005% to about 1% (w/v);

wherein the solubilizing agent is present in the formulation at a concentration of from about 0.001% to about 20% (v/v);

wherein the deactivating agent is (i) present in the formulation at a concentration of from about 0.06% to about 3% (w/v) if the deactivating agent is sodium hypochlorite;

wherein the deactivating agent is present in the formulation at a concentration of from about 5 mM to about 400 mM if the deactivating agent is dichloroisocyanurate; and

wherein each agent of the formulation remains substantially in solution at 22° C.

2. The method of claim 1 , wherein the corrosion-inhibiting agent is sodium bicarbonate.

3. The method of claim 1 , wherein the wetting agent is sodium dodecyl sulfate (SDS), lithium lauryl sulfate (LLS), saponin, cetyltrimethylammonium bromide (CTAB), or a polyoxyethylene detergent.

4. The method of claim 3 , wherein the wetting agent is SDS or LLS.

5. The method of claim 1 , wherein the solubilizing agent is an organic solvent.

6. The method of claim 5 , wherein the organic solvent is benzyl acetate, polysorbate 20 (PS20), or isopropanol.

7. The method of claim 1 , wherein the solubilizing agent is an emulsifying agent.

8. The method of claim 7 , wherein the emulsifying agent is polyoxyethylene sortitan mono-palmitate, lecithin, or ethylene glycol distearate.

9. The method of claim 1 , wherein the solubilizing agent is a fragrance.

10. The method of claim 1 , wherein the deactivating agent is sodium hypochlorite.

11. The method of claim 1 , wherein the deactivating agent is dichloroisocyanurate.

12. The method of claim 1 , further comprising dissolving a solid form of the solubilizing agent prior to step (c).

13. The method of claim 1 , further comprising the step of dissolving a solid form of the deactivating agent prior to step (d).

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2012
From: NELSON, NORMAN C.; BROWNE, KENNETH A.; DAI, LIZHONG; RUSSELL, JAMES; FILIPOWSKY, MARK E.; KAMINSKY, MARGARITA B.; KACIAN, DANIEL L.
To: GEN-PROBE INCORPORATED
Reel/Frame 029267/0274 →